Cost effectiveness of rituximab for non-Hodgkin's lymphoma: a systematic review.

Pharmacoeconomics

Institute for Health Economics and Clinical Epidemiology, The University Hospital of Cologne-AR, Cologne, Germany.

Published: July 2012

Background: The monoclonal antibody rituximab has shown clinical effectiveness in combination with chemotherapy for the treatment of non-Hodgkin's lymphoma (NHL) in several randomized controlled studies. Rituximab maintenance therapy is associated with significant improvement in progression-free and overall survival in patients with NHL. However, treatment with rituximab causes considerable costs for healthcare systems.

Objective: This article provides an overview of economic evaluations of rituximab and appraises their methodological quality.

Methods: A systematic literature search of cost-effectiveness studies on rituximab was carried out in nine electronic databases: MEDLINE, EMBASE, Cochrane Database of Systematic Reviews (CDSR), the German Agency of Health Technology Assessment (DAHTA) database, German Institute for Quality Improvement (DIQ)-Literatur, DIQ-Projekte, Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessments (HTA) database and Sozialmedizin (SOMED) [languages: English, German, Dutch, French, Spanish and Italian; publication period: 1998 to 2010]. Based on pre-specified inclusion criteria, cost-effectiveness studies were identified that compared standard chemotherapy with standard chemotherapy plus rituximab in patients with a subtype of NHL. The methodological quality of the studies was assessed using a quality checklist.

Results: Fourteen economic evaluations from seven different countries were included in the review. All economic evaluations reported incremental cost-effectiveness ratios (ICERs) for the add-on therapy with rituximab that were below the country-specific thresholds. The studies differed significantly in their characteristics and methodological rigour. Most studies lacked transparency regarding identification and justification of data. In several studies, the rationale for the model structure was not described appropriately.

Conclusion: Adding rituximab to standard chemotherapy is considered a cost-effective treatment option for NHL. However, the results of the analyses should be interpreted with caution due to methodological limitations.

Download full-text PDF

Source
http://dx.doi.org/10.2165/11591160-000000000-00000DOI Listing

Publication Analysis

Top Keywords

economic evaluations
12
standard chemotherapy
12
rituximab
9
non-hodgkin's lymphoma
8
studies rituximab
8
cost-effectiveness studies
8
health technology
8
studies
7
cost effectiveness
4
effectiveness rituximab
4

Similar Publications

Introduction: Despite recommendations from the WHO, antenatal care (ANC) coverage remains low in many low-income and middle-income countries (LMICs). Community health workers (CHWs) can play an important role in expanding ANC coverage through pregnancy identification, provision of health education, screening for complications, delivery of therapeutic care and referral to higher levels of care. However, despite the success of CHW programmes in various countries, WHO has called for additional research to develop evidence-based models that optimise CHW service delivery and that can be replicated across geographies.

View Article and Find Full Text PDF

Objectives: Chronic myeloid leukemia (CML) management now includes dose-reduction (DR) and treatment-free remission (TFR). Evaluating cost-effectiveness of lifelong-prescribed expensive tyrosine kinase inhibitors (TKIs) for CML is crucial. Prior cost-effectiveness evaluations state that imatinib is the favorable frontline TKI.

View Article and Find Full Text PDF

The COVID-19 pandemic increased maternal depression and anxiety, imperiling both mothers' own wellbeing and that of their children. To date, however, little is known about the extent to which these increases are attributable to economic hardships commonly experienced during the pandemic: income loss, job loss, and loss of health insurance. Few studies have examined the individual impacts of these hardships, and none have lasted beyond the first year of the pandemic.

View Article and Find Full Text PDF

Clinical comparative study of robot-assisted and traditional laparoscopic surgery in patients with cervical cancer: a retrospective cohort study.

BMC Surg

December 2024

Department of Phase I Clinical Research Center, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.

Background: A new era in minimally invasive surgery has been ushered in by Leonardo's robot surgical system, but the safety and effectiveness in cervical cancer is lake of evidence. This study aimed to compare the safety, effectiveness, and cost-effectiveness of robot-assisted laparoscopic radical hysterectomy (RRH) and conventional laparoscopic radical hysterectomy (LRH) in patients with cervical cancer.

Methods: Patients with cervical cancer who had radical surgery at the first affiliated Hospital of Chongqing Medical University between January 2017 and June 2022 were enrolled.

View Article and Find Full Text PDF

Ecological Corridors (ECs) are proposed as cost-effective solutions to improve ecological connectivity in fragmented landscapes. Planning the implementation of ECs must take into account landscape features as they affect the viability of the endeavor and the ECs associated costs. A novel set of geoprocessing tools were used to assess (i) economic viability; (ii) socioeconomic cost-effectiveness; and (iii) to determine priority targets for ECs establishment in a highly fragmented region of Atlantic Forest.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!